Journal of Leukocyte Biology BioLegend: Treg, Th17, Stem Cell
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on November 1, 2005

Published online before print October 4, 2005
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0705358v1
78/5/1043    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mocellin, S.
Right arrow Articles by Young, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mocellin, S.
Right arrow Articles by Young, H. A.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0705358

Received for publication July 4, 2005.
Revised August 3, 2005.
Accepted for publication August 8, 2005.

Article

Interleukin-10 and the immune response against cancer: a counterpoint

Simone Mocellin *@, Francesco M. Marincola {dagger}, and Howard A. Young {ddagger}

*Department of Oncological & Surgical Sciences, University of Padova, Italy; {dagger}Immunogenetics Laboratory, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland; and {ddagger}Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute, Frederick, Maryland

@ To whom correspondence should be addressed. E-mail: mocellins{at}hotmail.com.


  Abstract

Although interleukin-10 (IL-10) is commonly regarded as an anti-inflammatory, immunosuppressive cytokine that favors tumor escape from immune surveillance, a wealth of evidence is accumulating that IL-10 also possesses some immunostimulating properties. In fact, IL-10 has the pleiotropic ability of influencing positively and negatively the function of innate and adaptive immunity in different experimental models, which makes it questionable to merely categorize this cytokine as a target of anti-immune escape therapeutic strategies or rather, as an immunological adjuvant in the fight against cancer. Here, we review available data about the immunostimulating anticancer properties of IL-10, and in particular, we focus on the hypothesis that in contrast to what occurs in secondary lymphoid organs, IL-10 overexpression within the tumor microenvironment may catalyze cancer immune rejection.

Key Words: tumor-infiltrating macrophages • natural killer cell • tumor-associated antigen




This article has been cited by other articles:


Home page
 Int ImmunolHome page
A. Peterfalvi, E. Gomori, T. Magyarlaki, J. Pal, M. Banati, A. Javorhazy, J. Szekeres-Bartho, L. Szereday, and Z. Illes
Invariant V{alpha}7.2-J{alpha}33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells
Int. Immunol., October 16, 2008; (2008) dxn111v1.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Cacev, S. Radosevic, S. Krizanac, and S. Kapitanovic
Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression
Carcinogenesis, August 1, 2008; 29(8): 1572 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Ohtani, S. Nagai, S. Kondo, S. Mizuno, K. Nakamura, M. Tanabe, T. Takeuchi, S. Matsuda, and S. Koyasu
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells
Blood, August 1, 2008; 112(3): 635 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Kube, T.-D. Hua, F. von Bonin, N. Schoof, S. Zeynalova, M. Kloss, D. Gocht, B. Potthoff, M. Tzvetkov, J. Brockmoller, et al.
Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study
Clin. Cancer Res., June 15, 2008; 14(12): 3777 - 3784.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yotsumoto, K. Saegusa, and Y. Aramaki
Endosomal Translocation of CpG-Oligodeoxynucleotides Inhibits DNA-PKcs-Dependent IL-10 Production in Macrophages
J. Immunol., January 15, 2008; 180(2): 809 - 816.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. M. Montuenga and R. Pio
Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10
Eur. Respir. J., October 1, 2007; 30(4): 608 - 610.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Koehler, D. Kofler, A. Hombach, and H. Abken
CD28 Costimulation Overcomes Transforming Growth Factor-{beta}-Mediated Repression of Proliferation of Redirected Human CD4+ and CD8+ T Cells in an Antitumor Cell Attack
Cancer Res., March 1, 2007; 67(5): 2265 - 2273.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. P. Rao, T. Poutahidis, Z. Ge, P. R. Nambiar, C. Boussahmain, Y. Y. Wang, B. H. Horwitz, J. G. Fox, and S. E. Erdman
Innate Immune Inflammatory Response against Enteric Bacteria Helicobacter hepaticus Induces Mammary Adenocarcinoma in Mice.
Cancer Res., August 1, 2006; 66(15): 7395 - 7400.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the Society for Leukocyte Biology.